Table 1.
Baseline characteristics of the included studies.
| First author | Year | Country | Ethnicity | Number | Gender (M/F) | Age (years) | Interventions | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Control | GC | Control | GC | Control | GC | Control | GC | ||||
| van Raalte DH [13] | 2013 | Netherlands | Caucasian | 20 | 8 | 12 | 8/0 | 12/0 | 21±3 | 21±2 | Placebo | Prednisolone (30 mg) |
| van Raalte DH [27] | 2010 | Netherlands | Caucasian | 23 | 11 | 12 | 23/0 | 20–45 | Placebo | Prednisolone (30 mg) | ||
| van Raalte DH [31] | 2012 | Netherlands | Caucasian | 20 | 8 | 12 | 8/0 | 12/0 | 22±3 | 22±3 | Placebo | Prednisolone (30 mg) |
| Subramanian S [28] | 2006 | USA | Caucasian | 36 | 18 | 18 | 7/11 | 33.1±8 | Placebo | Dexamethasone (8 mg) | ||
| Hollingdal M [30] | 2002 | Denmark | Caucasian | 16 | 8 | 8 | - | 24.4±0.5 | Placebo | Prednisolone (30 mg) | ||
| Frazier B [29] | 2010 | USA | Caucasian | 86 | 43 | 43 | 0.419 | 28±5.5 | Placebo | Dexamethasone | ||
M – male; F – female; GC – glucocorticoids.